ConductScience.org, home

Paper36044100

GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Pedrosa MR and 8 others. Curr Atheroscler Rep, 2022. Cited by 52 papers, by iCite.

Cite this record

ConductScience Library. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Papers, record 36044100. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36044100

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
PubMed
Journal
Curr Atheroscler Rep
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
52
iCite
Relative citation ratio, by iCite
4.28
iCite
Revised in PubMed
2026-10-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pedrosa MRMaurício Reishttps://orcid.org/0000-0001-7966-2602
2Franco DRDenise Reishttps://orcid.org/0000-0003-4961-0638
3Gieremek HWHannah Waisberghttps://orcid.org/0000-0002-5167-8212
4Vidal CMCamila Maiahttps://orcid.org/0000-0003-4251-4184
5Bronzeri FFernandahttps://orcid.org/0000-0002-3660-3247
6de Cassia Rocha AAlexiahttps://orcid.org/0000-0002-9616-8427
7de Carvalho Cara LGLuis Gabrielhttps://orcid.org/0000-0001-6678-0415
8Fogo SLSofia Lenzihttps://orcid.org/0000-0002-6390-5056
9Eliaschewitz FGFreddy Goldberghttps://orcid.org/0000-0002-9283-1842

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Diabetes Mellitus, Type 2Major topic
Clinical Trials as Topic
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents
Liraglutide
Obesity
Weight Loss
Glucagon-Like Peptide-1 Receptor Agonists

Source PubMed

Download CSV of topics

References118

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134137731How glucagon-like peptide 1 receptor agonists work.Endocr Connect2021https://conductscience.org/library/papers/34137731PubMed
228950422Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.Diabetes Obes Metab2018https://conductscience.org/library/papers/28950422PubMed
322990267Cardiovascular risk assessment in the development of new drugs for obesity.JAMA2012https://conductscience.org/library/papers/22990267PubMed
431166153
Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.
J Am Heart Assoc2019https://conductscience.org/library/papers/31166153PubMed
532511781The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease.Clin Exp Pharmacol Physiol2020https://conductscience.org/library/papers/32511781PubMed
633984333Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis.J Pediatr2021https://conductscience.org/library/papers/33984333PubMed
734268675Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs).Diabetes Ther2021https://conductscience.org/library/papers/34268675PubMed
834235727Actions of glucagon-like peptide-1 receptor ligands in the gut.Br J Pharmacol2022https://conductscience.org/library/papers/34235727PubMed
934859263
Association between weight change and incidence of cardiovascular disease events and mortality among adults with type 2 diabetes: a systematic review of observational studies and behavioural intervention trials.
Diabetologia2022https://conductscience.org/library/papers/34859263PubMed
1035131037
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Lancet Diabetes Endocrinol2022https://conductscience.org/library/papers/35131037PubMed
1134170647Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med2021https://conductscience.org/library/papers/34170647PubMed
1220457158Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults.Gastroenterology2010https://conductscience.org/library/papers/20457158PubMed
131326760Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.Proc Natl Acad Sci U S A1992https://conductscience.org/library/papers/1326760PubMed
1428349386Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Clin Pharmacokinet2017https://conductscience.org/library/papers/28349386PubMed
1523812094Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.Int J Obes (Lond)2013https://conductscience.org/library/papers/23812094PubMed
1630067154Mechanisms of Insulin Action and Insulin Resistance.Physiol Rev2018https://conductscience.org/library/papers/30067154PubMed
1733068776GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.Mol Metab2021https://conductscience.org/library/papers/33068776PubMed
1833462955
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Diabetes Obes Metab2020https://conductscience.org/library/papers/33462955PubMed
1930473097LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.Mol Metab2018https://conductscience.org/library/papers/30473097PubMed
2021295846National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants.Lancet2011https://conductscience.org/library/papers/21295846PubMed

See all 118 referencesDownload CSV of references

Cited by41

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.

PMIDTitleJournalYearIn PapersSource
42761830Liraglutide and renal mitochondrial homeostasis: targeting the "metabolism-inflammation-lithogenesis" axis in metabolic syndrome.Front Pharmacol2026https://conductscience.org/library/papers/42761830PubMed
42583965Combined use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular protection.Indian J Pharmacol2026https://conductscience.org/library/papers/42583965PubMed
41965670Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists- preliminary study.J Transl Med2026https://conductscience.org/library/papers/41965670PubMed
41367404GLP-1 agonists and exercise: the future of lifestyle prioritization.Front Clin Diabetes Healthc2025https://conductscience.org/library/papers/41367404PubMed
41140718Goal Integration of Diabetes Self-Management Education and Psychosocial Support With Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes and Obesity.Clin Diabetes2025https://conductscience.org/library/papers/41140718PubMed
41001395GLP-1 receptor agonist increase retained gastric contents on EGD and same-day colonoscopy reduces this risk.Front Med (Lausanne)2025https://conductscience.org/library/papers/41001395PubMed
40765557Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.Int J Med Sci2025https://conductscience.org/library/papers/40765557PubMed
40732345Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40732345PubMed
40607222Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/40607222PubMed
40301134GLP-1R agonists: recent advances, current gaps, and future challenges.Mol Divers2026https://conductscience.org/library/papers/40301134PubMed
40149944Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.Biomolecules2025https://conductscience.org/library/papers/40149944PubMed
40143174Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40143174PubMed
40062102Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes.Cureus2025https://conductscience.org/library/papers/40062102PubMed
39990178Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.Diabetes Metab Syndr Obes2025https://conductscience.org/library/papers/39990178PubMed
39910018The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis.Obes Surg2025https://conductscience.org/library/papers/39910018PubMed
39858999The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.Medicina (Kaunas)2024https://conductscience.org/library/papers/39858999PubMed
39762910Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.Reprod Biol Endocrinol2025https://conductscience.org/library/papers/39762910PubMed
39283562Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis.Mol Cell Biochem2025https://conductscience.org/library/papers/39283562PubMed
39139038Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.Med Res Rev2025https://conductscience.org/library/papers/39139038PubMed
39099671Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.Front Endocrinol (Lausanne)2024https://conductscience.org/library/papers/39099671PubMed

See all 41 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GIP2695PubTator's text mininghttps://conductscience.org/library/genes/2695NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36044100

GET https://conductscience.org/api/papers/v1/36044100/references?page=2